Sarepta Therapeutics (SRPT) Operating Expenses (2010 - 2026)

Sarepta Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $372.4 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 64.37% year-over-year to $372.4 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 5.34% decrease from a year earlier, with the FY2025 full-year figure at $2.9 billion, up 72.1% from the prior year.
• Operating Expenses eased to $372.4 million in Q1 2026 per SRPT's latest filing, from $854.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $1.0 billion in Q1 2025 and bottomed at $297.7 million in Q1 2022.
• The 5-year median for Operating Expenses is $391.6 million (2023), against an average of $466.7 million.
• Across the five-year window, Operating Expenses soared 176.11% in 2025 and tumbled 64.37% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $365.3 million in 2022, then advanced by 1.89% to $372.2 million in 2023, then soared by 33.47% to $496.7 million in 2024, then surged by 72.03% to $854.5 million in 2025, then slumped by 56.42% to $372.4 million in 2026.
• Per Business Quant, the three latest SRPT Operating Expenses figures stand at $372.4 million (Q1 2026), $854.5 million (Q4 2025), and $502.7 million (Q3 2025).